Mofezolac
Based on 2 publication(s) in Google Scholar
Mofezolac, a non-steroidal anti-inflammatory drug (NSAID), is a selective, reversible and orally active COX-1 inhibitor with an IC50 of 1.44 nM. Mofezolac shows weak inhibitory activity on COX-2 (IC50 of 447 nM). Mofezolac can relieve pain and has anti-inflammatory activities.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.34%
- CAS. Nr.: 78967-07-4
- Formel: C19H17NO5
- Molecular Weight:339.34
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-13568
BenoxaprofenNonsteroidal Anti-inflammatory Agent -
HY-17009
IguratimodAnti-rheumatic Agent -
HY-134521
Diclofenac amideCOX-1/2 Inhibitor -
HY-114689
Diclofenac methyl esterDiclofenac Metabolite -
HY-N1390
SyringaldehydeCOX-2 Inhibitor -
HY-N0074
ByakangelicolCOX Inhibitor -
HY-145491
Resolvin D5Inflammation Inhibitor -
HY-15036A
Diclofenac diethylamineCOX Inhibitor -
HY-106443
ArimoclomolHSP Co-Inducer -
HY-13568R
Benoxaprofen (Standard)Anti-inflammatory/Antipyretic Compound -
HY-13219
TepoxalinCyclooxygenase/Lipoxygenase Inhibitor -
HY-17474A
Parecoxib SodiumCOX-2 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Mofezolac
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
COX-1 1.44 nM (IC50) |
COX-2 447 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Platelet | IC50 |
0.45 μM
Compound: 1
|
Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method
Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method
|
[PMID: 30590258] |
In Vitro
Mofezolac inhibits platelet aggregation with an IC50 of 0.45 μM in human platelet rich plasma (hPRP) assay[2].
Mofezolac slightly increase Bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor Bortezomib[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female ddY mice (4 week old, 18-27 g) injected with phenyl-p-benzoquinone (PQ)[1]
-
Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg
-
Administration:Oral administration; once
-
Result:Dose-dependently suppressed the writhing induced by PQinjection in mice.
Chemical Information
-
CAS. Nr. 78967-07-4
-
Appearance Solid
-
Molecular Weight 339.34
-
Formel C19H17NO5
-
Color White to off-white
-
SMILES
O=C(O)CC1=C(C2=CC=C(OC)C=C2)C(C3=CC=C(OC)C=C3)=NO1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]2026 Mar:352:151224. PMID: 41791543 -
Life Sci
Contribution of RAS, ROS and COX-1-derived prostanoids to the contractile profile of perivascular adipose tissue in cafeteria diet-induced obesity. [Abstract]2022 Nov 15:309:120994. PMID: 36155180
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (294.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. K Goto, et al. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat. 1998 Jul;56(4):245-54. [Content Brief]
[2]. Maria Laura Pati, et al. Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability. Eur J Med Chem. 2019 Feb 15;164:59-76. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9469 mL | 14.7345 mL | 29.4690 mL | 73.6724 mL |
| 5 mM | 0.5894 mL | 2.9469 mL | 5.8938 mL | 14.7345 mL | |
| 10 mM | 0.2947 mL | 1.4734 mL | 2.9469 mL | 7.3672 mL | |
| 15 mM | 0.1965 mL | 0.9823 mL | 1.9646 mL | 4.9115 mL | |
| 20 mM | 0.1473 mL | 0.7367 mL | 1.4734 mL | 3.6836 mL | |
| 25 mM | 0.1179 mL | 0.5894 mL | 1.1788 mL | 2.9469 mL | |
| 30 mM | 0.0982 mL | 0.4911 mL | 0.9823 mL | 2.4557 mL | |
| 40 mM | 0.0737 mL | 0.3684 mL | 0.7367 mL | 1.8418 mL | |
| 50 mM | 0.0589 mL | 0.2947 mL | 0.5894 mL | 1.4734 mL | |
| 60 mM | 0.0491 mL | 0.2456 mL | 0.4911 mL | 1.2279 mL | |
| 80 mM | 0.0368 mL | 0.1842 mL | 0.3684 mL | 0.9209 mL | |
| 100 mM | 0.0295 mL | 0.1473 mL | 0.2947 mL | 0.7367 mL |
Mofezolac Related Classifications
HY-120824 Related Classifications
Powered by Bioz